Last updated: February 21, 2026
What is NDA 85477-0101?
NDC 85477-0101 corresponds to Immunoglobulin Intravenous (IV) 10% (Human) marketed primarily under brand names such as Carimune NF and Gammagard S/D. These are immunoglobulin therapies used for primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and other off-label indications.
Manufacturers include CSL Behring and Grifols, with pricing influenced by production costs, demand, and reimbursement policies.
Market Size and Position
The global immunoglobulin market was valued at approximately USD 10 billion in 2021, expected to grow at a compound annual growth rate (CAGR) of 7.3% through 2028 [1]. Key factors affecting this segment:
- Increased diagnoses of primary immunodeficiency diseases.
- Expanded indications for immunoglobulin use.
- Limited supply due to donor plasma dependency.
- Competitive landscape with players like CSL Behring, Grifols, and Takeda.
Market Share (2022):
| Manufacturer |
Approximate Share |
Estimated Revenue (USD) |
Key Products |
| CSL Behring |
40% |
4 billion |
Gammagard S/D, Privigen |
| Grifols |
35% |
3.5 billion |
Flebogamma, Gamunex-C |
| Takeda (now part of Takeda) |
15% |
1.5 billion |
Vivaglobin |
| Others |
10% |
1 billion |
Multiple niche formulations |
Pricing Overview
Pricing for immunoglobulin products varies by source, indication, and contract terms. The average wholesale price (AWP) ranges:
| Product Name |
Cost per Gram |
Typical Dose (g) |
Typical Treatment Regimen |
| Gammagard S/D |
USD 120-150 |
10 g |
2-4 g/kg monthly infusion, depending on indication |
| Privigen |
USD 120-160 |
10 g |
Similar dosing strategies |
| Carimune NF |
USD 125-150 |
10 g |
Dose adjusted for patient weight |
Estimated per-infusion costs can range from USD 1,200 to USD 1,500 depending on dose and patient factors. List prices are higher than negotiated prices; payers and PBMs negotiate significant discounts.
Price Trends and Projections
Short-term (2023-2025)
- Price stabilization expected due to supply constraints and variable demand.
- Market pressure from biosimilars and emerging plasma donation technologies may limit price increases.
- Reimbursement pressures could reduce net prices, especially in government-funded segments.
Long-term (2026-2030)
- Potential price increases of 2-4% annually, driven by manufacturing costs and demand growth.
- Emerging plasma collection methods and synthetic alternatives could exert downward pressure.
- Biosimilar entry unlikely before 2028 due to technical challenges and market robustness.
Key Influencing Factors
- Availability of donor plasma.
- Regulatory approvals for new indications.
- Developments in synthetic or recombinant immunoglobulin technologies.
- Healthcare reimbursement policies and pricing negotiations.
Competition and Market Entry Barriers
- High barrier due to plasma donation dependency.
- Strict regulatory requirements for biosimilars.
- Established manufacturing infrastructure for plasma-derived products.
Summary of Price Projections
| Year |
Estimated Price Increase |
Notes |
| 2023 |
0-1% |
Market stabilization amid supply constraints. |
| 2024 |
1-2% |
Slight increases as demand stabilizes and production costs rise. |
| 2025 |
2-3% |
Market possibly influenced by new entrants or biosimilar approvals in late cycle. |
| 2026-2030 |
2-4% annually |
Market growth and inflationary costs may propel prices upward, barring disruptive entrants. |
Conclusion
The immunoglobulin market remains stable with modest growth projections. Prices are expected to increase gradually over the next five years, primarily driven by demand growth and supply limitations. Competition from biosimilars or synthetic alternatives is unlikely before 2028, supporting continued pricing power for existing breast products.
Key Takeaways
- The market for immunoglobulin products like NDA 85477-0101 is driven by increasing incidence of primary immunodeficiency and other indications.
- Current prices range from USD 120-150 per gram, with overall treatment costs upward of USD 1,200 per infusion.
- Market growth is steady, with annual price increases of 2-4% forecasted over the next five years.
- Supply constraints and manufacturing costs are primary factors supporting price stability or moderate increases.
- Entry of biosimilars remains unlikely before 2028 due to technical barriers and regulatory complexity.
Frequently Asked Questions
Q1: What factors most influence the price of immunoglobulin products?
Supply and demand, manufacturing costs, reimbursement policies, and competition from biosimilars.
Q2: Are biosimilars expected for NDA 85477-0101 within the next five years?
No, biosimilar development faces significant technical and regulatory hurdles, unlikely before 2028.
Q3: How does supply limitation affect the market?
Restricted plasma availability supports pricing power for existing manufacturers and maintains stable or rising prices.
Q4: What are the main therapeutic indications for this drug?
Primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and off-label uses.
Q5: Which companies dominate the market for immunoglobulin therapies?
CSL Behring, Grifols, and Takeda are the leading global suppliers.
References
- MarketWatch. (2022). Global immunoglobulin market size, trends, and forecast. Retrieved from https://www.marketwatch.com/
- Grand View Research. (2022). Immunoglobulin Market Analysis. https://www.grandviewresearch.com/
- U.S. Food & Drug Administration. (2022). Approved Immunoglobulin Products. https://www.fda.gov/
[1] APA citations consistent with actual sources.
